In cPLA2/cells, the level of cyclin Dl is very low, its induction is markedly delayed, and the level is reduced compared with WT cells

In cPLA2/cells, the level of cyclin Dl is very low, its induction is markedly delayed, and the level is reduced compared with WT cells. have important therapeutic benefits in disease mechanisms that involve excessive cell proliferation, in particular, cancer and proliferative glomerulopathies. Naini, S. M., Choukroun, G. J., Ryan, J. R., Hentschel, D. M., Shah, J. V., Bonventre, J. V. Cytosolic phospholipase A2 regulates G1progression through modulating FOXO1 activity. Keywords: zebrafish, cell cycle, p27Kip1, cyclin D1, PGE2 Phospholipase A2(PLA2) comprises a family of enzymes that hydrolyze phospholipids to generate free fatty acids and lysophospholipids. Among these phospholipases, the group IVA cytosolic large molecular mass form of PLA2(cPLA2) is a major source of arachidonic acid (AA), an important lipid second messenger (14) that can be converted by cyclooxygenase, lipoxygenase, and cytochrome p450 sulfaisodimidine enzymes into prostaglandins (PGs), leukotrienes, hydroxyeicosatetraenoic acids, epoxyeicosatrienoic acids, and dihydroxyeicosatrienoic acids, products that are involved in the regulation of a number of cellular processes including inflammation, mitogenesis, and cell differentiation (17). Several metabolites produced by cPLA2 activity, including AA, lysophosphatidic acid, thromboxane A2, and PGs, have been implicated in the regulation of DNA synthesis and cell proliferation (812). However , the exact mechanism by which these eicosanoid products regulate proliferation is poorly understood. Furthermore, many studies addressing this issue have relied upon inhibitors, which cannot be expected to be entirely specific to cPLA2. We previously reported the effects of deletion of the cPLA2 locus in the ApcMinmouse, sulfaisodimidine one of the most widely used mouse models intended for colon cancer (13). Mice carrying the Apcminmutation on a c57BL/6J background spontaneously develop many tumors (adenomas sulfaisodimidine or polyps) due to a dominant germ collection mutation in the adenomatous polyposis coli (apc) gene, the mouse homolog BST2 of the human APC gene. APCmin/+cPLA2/animals show an 83% reduction in tumor number in the small intestine when compared with APCmin/+cPLA2+/double heterozygotes and Apcmin/+cPLA2+/+littermates. Interestingly, APCmin/+mPGES-1/, which lack prostaglandin E2(PGE2), showed the same amount of reduction in tumor polyp size and number as the APCmin/+cPLA2/mice, suggesting that the effects of cPLA2 deletion on cell proliferation in this mouse model sulfaisodimidine may be PGE2dependent (14). The aim of the present study was to determine the effect of cPLA2 on the G0/G1phase of the cell cycle. We used primary cells derived from cPLA2/mice and littermate cPLA2+/+mice forin vitroassays and the zebrafish model for ourin vivostudies. The zebrafish has evolved as a facilein vivomodel to study human disease because many genes are highly conserved between the 2 vertebrate species, including cyclins, cyclin-dependent kinases (Cdks), and inhibitors of Cdks (15, 16). Expression profiles of cell cycle regulatory genes have shown that genes of major importance to G1and S phases of the cell cycle, including orthologs of the retinoblastoma (pRb), cyclin D1, and cyclin E1, were expressed at very low levels early after fertilization and increased markedly between 3 and 6 h postfertilization (hpf), making zebrafish a suitablein vivomodel to study early cell division, tissue-specific cellular proliferation, and more broadly, the role of cell cycle genes in development and disease (15). Here, we recognized thecpla2gene family in zebrafish, and we show a novel role intended for cPLA2 in the regulation of G1phase of the cell cycle. Lack of cPLA2 activity resulted in sulfaisodimidine lower levels of cyclin D1, higher levels of p27Kip1, a marked decrease in kinase activity associated with Cdk4, and prolongation of G1phase. This function of cPLA2 is dependent on its phospholipase.